Alemtuzumab and multiple sclerosis: Is it safe?

Neurology

Volumn 83, Issue 1, 2014, Pages 17-18

  Bourdette, Dennis ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON;

AGRANULOCYTOSIS; AUSTRALIA; BRAIN HEMORRHAGE; BURKITT LYMPHOMA; CANADA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); DRUG SAFETY; EDITORIAL; ESOPHAGUS CANDIDIASIS; EUROPE; FATALITY; FOOD AND DRUG ADMINISTRATION; GOODPASTURE SYNDROME; GRAVES DISEASE; HEMOLYTIC ANEMIA; HERPES ZOSTER; HUMAN; HYPERTHYROIDISM; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LISTERIOSIS; LYMPHOCYTE; MONOCYTE; MULTIPLE SCLEROSIS; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE; OPPORTUNISTIC INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECURRENCE RISK; RISK FACTOR; THROMBOCYTOPENIC PURPURA; THYROID CANCER; THYROID DISEASE; THYROIDECTOMY;

ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; MULTIPLE SCLEROSIS;

EID: 84903999246     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000554     Document Type: Editorial

References (9)

1. Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc 2014;89: 225-240.
2. Menge T, Stüve O, Kieseier BC, Hartung HP. Alemtuzumab: the advantages and challenges of a novel therapy in MS. Neurology 2014;83: 87-97.
3. FDA rejects MS drug Lemtrada. Available at: http://www. webmd.com/multiple-sclerosis/news/20131230/fda-rejects-msdrug-lemtrada. Accessed April 18, 2014.
4. FDA reviewers raise concern about alemtuzumab in MS. Available at: http://www.medscape.com/viewarticle/814121. Accessed April 18, 2014.
5. Coles AJ, Cox A, le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006;253: 98-108.
6. Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359: 1786-1801.
7. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380: 1819-1828.
8. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after diseasemodifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380: 1829-1839.
9. Kraimps JL, Bouin-Pineau MH, Mathonnet M, et al. Multicentre study of thyroid nodules in patients with Graves disease. Br J Surg 2000;87: 1111-1113.